Target 5 types of solid cancer including non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, rectal cancer, and pancreatic cancer
Proven to increase anti-cancer activity and treatment efficacy
[팜뉴스=이권구 기자] Neoimmuntech, which develops the first-in-class next-generation immune anticancer drug that induces T-cell amplification, launched its own’NT-I7′ (efineptakin alfa) and the global pharmaceutical company Merck’s immune anticancer drug (PD-1 inhibitor)’kit On the 23rd, it was announced on the 23rd that the first phase 2 clinical trial was completed after the dose escalation stage 1b clinical trial was completed at the MD Anderson Cancer Center for the combined administration of Luda®’
This clinical target indication is 5 types of recurrent or refractory advanced solid cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple negative breast cancer (TNBC), rectal cancer (MSS-CRC), and pancreatic cancer (PC). , This clinical trial is one of four major clinical trials with global pharmaceutical companies BMS, Roche, and Merck, which have commercialized immune checkpoint inhibitors.
Through this clinical trial, Neo-Imuntech plans to co-administer’NT-I7′ and’Kitruda’ to clinical patients and evaluate the safety and treatment efficacy of the combined drug. It will be announced at.
The total number of clinical patients recruited is 150, and triple-negative breast cancer, non-small cell lung cancer, and small cell lung cancer patients are targeting patients who have already received immune checkpoint inhibitor treatment, and rectal cancer and pancreatic cancer patients are targeting patients who have not been treated with immune checkpoint inhibitors. The clinical trial proceeds. The company expects that through clinical trials for each patient group, more precise analysis and key results for the treatment regimen will be possible.
Yang Se-hwan, CEO of Neoimmuntech, said, “By administering Kitruda in combination with NT-I7, we plan to demonstrate whether it has increased anti-cancer activity and whether it has anti-cancer effects targeting tumors resistant to immune checkpoint inhibitors.” We look forward to presenting new treatment alternatives.”
Copyright © Farm News Unauthorized reproduction and redistribution prohibited